Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. cl-io

CL-IO SIGNED

Commercial feasibility of non-pathogenic Clostridium-Mediated Cancer Immunotherapy: leveraging the presence of tumour hypoxia & necrosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CL-IO project word cloud

Explore the words cloud of the CL-IO project. It provides you a very rough idea of what is the project "CL-IO" about.

modified    necrosis    release    hypoxia    bacteria    optimal    off    prepare    push    cancers    radiotherapy    urgency    inclusion    cancer    io    commercial    tumors    respect    clostridium    antibody    incidence    feasibility    sought    stereotactic    colonise    model    weapons    solid    technological    therapeutic    precision    business    gain    tumour    poc    team    cellular    benefit    lung    overcome    strategy    inhibitor    factories    watch    proven    immunotherapy    exact    cl    com    trimodal    lambin    routes    14    commercialisation    combating    immunotherapies    accelerator    strategic    selectively    hypoxic    hypoximmuno    checkpoint    regions    immunocytokine    delivering    innovative    producing    modality    escape    site    l19    patients    powerful    251022032    immune    positioning    despite    break    minority    first    malignancies    market    dictated    mortality    genetically    experts    act    necrotic    vimeo    proof    erc    limited    start    immunotherapeutics    limitation    tumours    strategies    suppression    agents    therapy    worldwide    ip    position    il2    prof    spin    mechanisms    rates    immunotherapeutic    https   

Project "CL-IO" data sheet

The following table provides information about the project.

Coordinator		 UNIVERSITEIT MAASTRICHT 

Organization address
address: Minderbroedersberg 4-6
city: MAASTRICHT
postcode: 6200 MD
website: http://www.maastrichtuniversity.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Netherlands [NL]
 Total cost 150˙802 €
 EC max contribution 150˙000 € (99%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2018
 Duration (year-month-day) from 2018-10-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT MAASTRICHT NL (MAASTRICHT) coordinator 150˙000.00

Map

 Project objective

Immunotherapeutic strategies are powerful weapons in combating malignancies. However, only a minority of patients benefit from this therapeutic modality, as tumours develop mechanisms of immune escape and suppression and uptake of (antibody-based) agents in tumors is limited. The urgency of investigating novel strategic approaches is dictated by the high incidence and mortality rates of cancer worldwide. Lung cancer, in particular, is the leading cancer with respect to incidence and mortality (14% of new cancers). In the ERC Advanced “HYPOXIMMUNO”, Prof. Lambin and his team have investigated the trimodal therapy involving high precision Stereotactic Radiotherapy, hypoxia/necrosis targeting and tumour specific immunotherapy (immunocytokine L19-IL2 to “push the accelerator” with a checkpoint inhibitor to “release the break”). Despite promising results, the delivery of immunotherapeutics to the tumour site has proven to be challenging. Prof. Lambin and his team have sought to overcome this limitation with the inclusion of genetically-modified Clostridium bacteria as optimal delivery system capable of effectively delivering immunotherapeutics within the tumour. These Clostridium-bacteria selectively colonise the hypoxic/necrotic regions present in solid tumours and act as cellular factories capable of continuously producing tumour-specific immunotherapies within the tumour (watch https://vimeo.com/251022032 ). In this ERC PoC project, a team of technological and commercial experts will investigate the commercial feasibility of this innovative approach. We will prepare the first steps towards the start-up of a spin-off, by defining the exact business strategy, model and positioning for commercial success. We will develop the business strategy based on the technological aspects, the market needs and trends, and the IP-position. During CL-IO, we will gain technical and commercial proof-of-concept, providing the necessary information for potential commercialisation routes.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CL-IO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CL-IO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

IMMUNOTHROMBOSIS (2019)

Cross-talk between platelets and immunity - implications for host homeostasis and defense

Read More  

RODRESET (2019)

Development of novel optogenetic approaches for improving vision in macular degeneration

Read More